Orally Disintegrating Tablet Market

Orally Disintegrating Tablet Market Outlook (2024 to 2034)

The global orally disintegrating tablet market has been estimated at a valuation of US$ 24.45 billion and is forecasted to rise at a CAGR of 11.5% to reach US$ 72.68 billion by the end of 2034.

The market is witnessing significant growth, aiding individuals of diverse ages in swallowing tablets effortlessly. Demand for orally disintegrating tablets (ODTs) is rising fast, especially among the elderly, due to muscle weakness that makes swallowing challenging. Increasing aging population is a key driver behind increased tablet sales. The rapid absorption of medication in the mouth accelerates entry into the bloodstream, rendering oral disintegrating tablets particularly suitable for conditions like neurological disorders, epilepsy, and sleep disorders.

Manufacturing oral disintegrating tablets involves loose compression tableting, enabling dissolution on the tongue rather than swallowing whole. This process benefits individuals with swallowing difficulties, contributing significantly to the market's growth.

Key Market Growth Drivers

• ODTs have the feature of rapid absorption, leading to a quick recovery process. More people are looking for ways to heal faster, attracting them toward using ODTs.
• As these medicines do not need to be swallowed, they eliminate the risk of choking or gagging, which is particularly beneficial for infants prone to choking on regular tablets.
• These tablets require no additional liquid for swallowing, making them convenient for consumption anywhere, anytime. With busy lifestyles, more people find these tablets facilitating easy medication intake.
• Patients with gastrointestinal issues opt for these tablets due to difficulties swallowing traditional ones, easing medication intake without needing assistance.
• Suppliers are focusing on aspects like aftertaste and mouthfeel to enhance the appeal of ODTs. With reduced bitterness and faster action, ODTs attract a broader patient base seeking improved taste and experience.
• Unlike traditional tablets requiring precise administration, ODTs offer ease and accuracy, promoting better patient adherence to treatment regimens.
• ODTs boast a longer shelf life, attributed to improved stability and manufacturing processes, providing ODT suppliers with a competitive edge over traditional tablets.

Report Attribute	Detail
Orally Disintegrating Table Market Size (2024E)	US$ 24.45 Billion
Forecasted Market Value (2034F)	US$ 72.68 Billion
Global Market Growth Rate (2024 to 2034)	11.5% CAGR
Canada Market Growth Rate (2024 to 2034)	12.2% CAGR
Brazil Market Value (2034F)	US$ 1 Billion
North America Market Share (2024E)	37.1%
Latin America Market Share (2034F)	3.4%
Key Companies Profiled	Johnson & Johnson Services Inc; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; Eli Lily and Company; Dr. Reddy’s Laboratories Ltd; Mylan N.V.; Bausch Health; GlaxoSmithKline Plc; Merck & Co Inc.; AstraZeneca; Bayer AG; F Hoffman-La Roche Ltd.

Why are Orally Disintegrating Tablets Preferred over Traditional Tablets and Capsules?

“Ability of ODTs to Dissolve Rapidly in Mouth Without Water Intake”

In recent years, orally disintegrating tablets (ODTs) have gained significant popularity as an alternative to traditional tablets and capsules due to improved patient compliance. These innovative tablets dissolve rapidly in the mouth, typically within minutes, and can be taken without the need for water, offering a convenient and accessible option for many individuals.

The challenge of swallowing traditional medications, especially for babies, young children, and the elderly, has been effectively addressed by the introduction of orally disintegrating tablets. To further enhance their performance and desirability, ongoing developments in this area have led to the introduction of various orally disintegrating pills with improved characteristics, including better taste and faster disintegration. These advancements are contributing to the expansion of the orally disintegrating tablet market size.

“Escalated Bioavailability Enhancing Effectiveness of Protein- and Peptide-Based Drugs”

Oral administration of medications often results in a significant reduction in the amount of drug reaching the bloodstream due to first-pass metabolism. Orally disintegrating tablets play a crucial role in overcoming this challenge by bypassing the first-pass metabolism issue, thereby enhancing the bioavailability of the administered medicines. This attribute is particularly advantageous for protein and peptide-based therapies, where achieving high bioavailability is essential for therapeutic effectiveness.

ODTs with improved bioavailability offer a promising solution for the delivery of high molecular weight drugs, addressing a critical need in the pharmaceutical industry. This innovative approach not only enhances the therapeutic effectiveness of protein and peptide-based medications but also opens up new possibilities for the development and delivery of advanced pharmaceutical treatments, positioning ODTs as a valuable and increasingly important segment of the pharmaceutical market. All of these factors are leading to orally disintegrating tablet market growth.

What is Restricting ODT Suppliers from Reaching Their Full Potential in the Market?

“High Cost of Orally Dissolving Tablets Limiting Adoption among Low-income Patient Groups”

High costs of ODTs present a significant challenge to the market's growth trajectory. The production costs of ODTs are notably higher compared to traditional tablets or capsules. As a result, the affordability of ODTs is a major concern for patients with limited budgets, which limits the accessibility and adoption of ODTs. This can particularly impact the demand for ODTs in lower-income countries with cost-sensitive healthcare environments.

Country-wise Analysis

The market in Chile is forecasted to expand at a CAGR of 9.9% from 2024 to 2034. The country is evaluated to occupy an orally disintegrating tablet market share of 21.5% in Latin America by 2034.

Which Factors are Making the United States a Profit Hub for ODT Suppliers?

“Growing Need for Pediatric and Geriatric Formulations and Patient-friendly Dosage Forms”

Attribute	United States
Market Value (2024E)	US$ 7.47 Billion
Growth Rate (2024 to 2034)	11.3% CAGR
Projected Value (2034F)	US$ 21.78 Billion

The market for orally disintegrating tablets in the United States is being driven by rising demand for pediatric and geriatric formulations, as well as the need for patient-friendly dosage forms for people who have difficulty swallowing or are averse to traditional tablets. The rising prevalence of chronic diseases, such as cardiovascular disorders, mental health conditions, and allergies, is driving the development of orally disintegrating tablets in a variety of therapeutic areas across the country.

Will Focus on Innovation in Drug Formulations Push Sales of ODTs in Brazil?

“Improvements in Taste and Stability of ODTs Enhancing Patient Acceptance and Compliance”

Attribute	Brazil
Market Value (2024E)	US$ 397 Million
Growth Rate (2024 to 2034)	9.8% CAGR
Projected Value (2034F)	US$ 1.01 Billion

Taste-masking techniques, super disintegrants, and freeze-drying technology are examples of technological advancements in formulation and manufacturing processes that improve the palatability, stability, and disintegration properties of ODTs. These advancements are boosting patient acceptance and compliance in Brazil. Strategic collaborations between pharmaceutical companies and contract manufacturing organizations (CMOs) are facilitating the development and commercialization of innovative drug formulations, which is one of the key orally disintegrating tablet market trends in the country.

Category-wise Insights

Based on distribution channel, the hospital pharmacy segment is evaluated to expand at a noteworthy CAGR of 12.7% from 2024 to 2034. With rising healthcare spending worldwide, there is a parallel increase in demand for pharmaceuticals, especially within hospital settings where a wide range of medical conditions are treated.

Which Drug Class Accounts for Significant Revenue Generation?

“Rising Sales of Orally Disintegrating Anti-Psychotics to Improve Patient Compliance”

Attribute	Anti-Psychotics
Segment Value (2024E)	US$ 4.72 Billion
Growth Rate (2024 to 2034)	12.8% CAGR
Projected Value (2034F)	US$ 15.76 Billion

Anti-psychotics help reduce psychotic symptoms such as delusions and hallucinations including paranoia and hearing voices, reducing anxiety and stress. The availability of anti-psychotics in the ODT form enhances convenience for patients, thus driving patient compliance.

Why are ODTs Considered Valuable in the Management of CNS Symptoms?

“Orally Disintegrating Tablets Playing Crucial Role in Promoting Faster Healing”

Attribute	CNS Disease
Segment Value (2024E)	US$ 14.15 Billion
Growth Rate (2024 to 2034)	12.6% CAGR
Projected Value (2034F)	US$ 46.17 Billion

CNS disease includes a broad spectrum of diseases including brain and spinal cord. Orally disintegrating tablets often help in reducing symptoms and pains in such diseases and help the patient to heal faster.

Competitive Landscape

The market for orally disintegrating tablets (ODTs) is extremely competitive, with several established and emerging players vying for market share.
Companies engage in the research, development, and commercialization of ODTs and other pharmaceutical products.

Product innovation, strategic partnerships and collaborations, mergers and acquisitions, and geographical expansion are some of the key strategies used by these players to maintain and grow their market share. Key players in the orally disintegrating tablet market are adapting themselves to the evolving market trends such as oral antivirals and oral solid dosage contracts.

Fact.MR provides detailed information about the price points of key orally disintegrating tablet manufacturers positioned across the world, sales growth, production capacity, and speculative technological expansion in this new market report.

Key Segments of OTD Market Research

• By Drug Class :

  • Anti-Psychotics
  • Anti-Epileptics
  • CNS Stimulants
  • Anxiolytics
  • Anti-Parkinsonian Drugs
  • Anti-Hypertensives
  • NSAIDs
  • Anti-Allergy Drugs
  • Proton Pump Inhibitors
  • Others

• By Disease Indication :

  • CNS Disease
  • GI Disease
  • CVS Disorders
  • Allergy
  • Others

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

• By Region :

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa